Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
DateTimeSourceHeadlineSymbolCompany
07/17/20245:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
07/16/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
07/15/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
07/12/20244:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
07/12/20244:23PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:ZVRAZevra Therapeutics Inc
07/09/20249:23AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
07/09/20249:00AMGlobeNewswire Inc.Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
06/25/20247:30AMGlobeNewswire Inc.Zevra Therapeutics Expands Executive Leadership TeamNASDAQ:ZVRAZevra Therapeutics Inc
06/18/20247:30AMGlobeNewswire Inc.Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
06/18/20247:30AMPR Newswire (US)Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
06/14/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVRAZevra Therapeutics Inc
06/04/20245:13PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVRAZevra Therapeutics Inc
06/03/202411:00AMGlobeNewswire Inc.Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
05/15/20249:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
05/15/20249:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
05/15/20249:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
05/15/20249:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
05/15/20249:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
05/13/20244:47PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
05/09/20244:34PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
05/09/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor EventsNASDAQ:ZVRAZevra Therapeutics Inc
05/08/20247:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
05/08/20247:00AMGlobeNewswire Inc.Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
05/01/20247:30AMGlobeNewswire Inc.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024NASDAQ:ZVRAZevra Therapeutics Inc
04/29/20247:30AMGlobeNewswire Inc.Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024NASDAQ:ZVRAZevra Therapeutics Inc
04/15/20245:01PMGlobeNewswire Inc.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
04/10/20247:30AMGlobeNewswire Inc.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityNASDAQ:ZVRAZevra Therapeutics Inc
03/28/20244:32PMGlobeNewswire Inc.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
03/28/20247:42AMIH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ZVRAZevra Therapeutics Inc
03/26/20244:30PMGlobeNewswire Inc.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA